JP7477719B2 - 単位用量乾燥粉末吸入器 - Google Patents
単位用量乾燥粉末吸入器 Download PDFInfo
- Publication number
- JP7477719B2 JP7477719B2 JP2023513476A JP2023513476A JP7477719B2 JP 7477719 B2 JP7477719 B2 JP 7477719B2 JP 2023513476 A JP2023513476 A JP 2023513476A JP 2023513476 A JP2023513476 A JP 2023513476A JP 7477719 B2 JP7477719 B2 JP 7477719B2
- Authority
- JP
- Japan
- Prior art keywords
- bowl
- tube
- air inlet
- air outlet
- unit dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940112141 dry powder inhaler Drugs 0.000 title description 3
- 239000000843 powder Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 238000007789 sealing Methods 0.000 claims description 12
- 239000011888 foil Substances 0.000 claims description 11
- 230000000717 retained effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000004922 lacquer Substances 0.000 description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 3
- 229960001469 fluticasone furoate Drugs 0.000 description 3
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 3
- 229960004735 indacaterol maleate Drugs 0.000 description 3
- IREJFXIHXRZFER-PCBAQXHCSA-N indacaterol maleate Chemical compound OC(=O)\C=C/C(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 IREJFXIHXRZFER-PCBAQXHCSA-N 0.000 description 3
- 239000011295 pitch Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- 229940015042 glycopyrrolate Drugs 0.000 description 2
- 229960002462 glycopyrronium bromide Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229960002744 mometasone furoate Drugs 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 229960005018 salmeterol xinafoate Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960004026 vilanterol Drugs 0.000 description 2
- DAFYYTQWSAWIGS-DEOSSOPVSA-N vilanterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 DAFYYTQWSAWIGS-DEOSSOPVSA-N 0.000 description 2
- 229940020910 vilanterol and umeclidinium bromide Drugs 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 1
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- UXZDMXYRRQJIBJ-IBGZPJMESA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)-n-[(3,4,5-trifluorophenyl)methyl]carbamate Chemical compound FC1=CC=CC(N(CC=2C=C(F)C(F)=C(F)C=2)C(=O)O[C@@H]2C3CCN(CC3)C2)=C1 UXZDMXYRRQJIBJ-IBGZPJMESA-N 0.000 description 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
- MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 1
- CWRNUVNMUYSOFQ-ABHLOGGPSA-M [Br-].C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c3ccccc3)c4ccccc4)C2 Chemical compound [Br-].C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c3ccccc3)c4ccccc4)C2 CWRNUVNMUYSOFQ-ABHLOGGPSA-M 0.000 description 1
- 229940019903 aclidinium Drugs 0.000 description 1
- 229960005012 aclidinium bromide Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
- 229940057282 albuterol sulfate Drugs 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950010713 carmoterol Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229950002590 darotropium bromide Drugs 0.000 description 1
- FVTWTVQXNAJTQP-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol Chemical compound C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- SYCWERNQGSKYAG-QVRIGTRMSA-N hydron;8-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1h-quinolin-2-one;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 SYCWERNQGSKYAG-QVRIGTRMSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 229940042006 metaproterenol sulfate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950006498 tarafenacin Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 229960004258 umeclidinium Drugs 0.000 description 1
- 229960004541 umeclidinium bromide Drugs 0.000 description 1
- PEJHHXHHNGORMP-AVADPIKZSA-M umeclidinium bromide Chemical compound [Br-].C=1C=CC=CC=1C([C@@]12CC[N@@+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 PEJHHXHHNGORMP-AVADPIKZSA-M 0.000 description 1
- KLOLZALDXGTNQE-JIDHJSLPSA-N vilanterol trifenate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1.C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 KLOLZALDXGTNQE-JIDHJSLPSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0061—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using pre-packed dosages having an insert inside
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
- A61M2207/10—Device therefor
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Description
・空洞が形成された基部材であって、空洞が、粉末を収容するボウル、及びボウル内に開口するチャネルを備える、基部材と、
・空気出口及び空気入口を提供する別個の部分を有するチャネル内のチューブであって、空気出口が空気入口よりもボウルから遠い、チューブと、
・空洞を封止する、箔または箔積層体などの蓋材と、
・取り外されたときに、空気入口及び空気出口を露出させる少なくとも1つの着脱可能部分と
を備え、
チューブが、チャネルの上部と同じ高さの平坦な上側を有する。
・基部材に空洞を形成するステップであって、各空洞が、ボウル、及びボウル内に開口するチャネルを備える、ステップと、
・ボウルに粉末を充填するステップと、
・チャネル内に空気出口及び空気入口を提供する別個の部分を有するチューブを配置するステップであって、空気出口が、空気入口よりもボウルから遠くにあり、チューブが、チャネルの上部と同じ高さの平坦な上側を有する、ステップと、
・蓋材で空洞を封止するステップと、同時に、またはいずれかの順序で、
・取り外されたときに、空気入口及び空気出口を露出させる着脱可能部分を形成するステップと、
・個々のディスペンサ、または複数対のディスペンサ、または複数のディスペンサを有するストリップを形成するために、基部材及び蓋材を切断するステップと
を含む。
Claims (13)
- 吸入用の乾燥粉末を収容するブリスタの形態での単位用量ディスペンサであって、前記ブリスタが、
・空洞が形成された基部材であって、前記空洞が、前記粉末を収容するボウル、及び前記ボウル内に開口するチャネルを備える、基部材と、
・前記空洞を封止する、箔または箔積層体などの蓋材と、
・取り外されたときに、前記ボウルへの空気入口、及び前記チャネルを介して前記ボウルからの空気出口を露出させる少なくとも1つの着脱可能部分と、
を備え、
前記チャネルが、前記空気出口及び前記空気入口を提供する別個の部分を有するチューブを収容し、前記空気出口を提供する部分と前記空気入口を提供する部分とは並行に配置され、前記空気出口が、前記空気入口よりも前記ボウルから遠く、
前記チューブが、前記チャネルの上部と同じ高さであり、前記空気出口を提供する部分と前記空気入口を提供する部分とを共通に覆う平坦な上側を有する、
単位用量ディスペンサ。 - 前記チューブが、半円形の断面を有し、その湾曲した下側は、締まり嵌めによって前記チャネル内に保持されるように、サイズ及び形状が前記チャネルに対応する、請求項1に記載の単位用量ディスペンサ。
- 前記蓋材が、前記チューブの前記平坦な上側に接合される、請求項1または2に記載の単位用量ディスペンサ。
- 前記チューブが、中央空気出口部と、前記中央空気出口部の両側に1つずつある2つの空気入口部と、に長手方向に分割される、請求項1から3のいずれか一項に記載の単位用量ディスペンサ。
- 前記2つの空気入口部が、前記中央空気出口部よりも前記ボウル内にさらに延在する、請求項4に記載の単位用量ディスペンサ。
- 前記ボウル内への前記空気入口部の延長部が、前記ボウルの内面と一致するように成形される、請求項5に記載の単位用量ディスペンサ。
- 前記着脱可能部分と、前記ブリスタの残りの部分との間で、前記基部材及び/または前記蓋材に穿孔などの脆弱線を、ならびに/あるいは、前記基部材及び/または前記蓋材の一方または両方の縁部にノッチを、有する、請求項1から6のいずれか一項に記載の単位用量ディスペンサ。
- 請求項1から7のいずれか一項に記載の一対のディスペンサであって、両方のブリスタ内の前記粉末を同時に吸入できるように、互いに密着する、一対のディスペンサ。
- 請求項1から7のいずれか一項に記載のディスペンサを複数備えるストリップであって、複数日分の粉末供給を提供し、各ディスペンサが、前記ストリップの残りの部分から着脱可能である、ストリップ。
- 請求項1から9のいずれか一項に記載の単位用量ディスペンサを製造するプロセスであって、前記プロセスが、
・基部材に空洞を形成するステップであって、前記空洞それぞれが、ボウル、及び前記ボウル内に開口するチャネルを備える、ステップと、
・前記ボウルに前記粉末を充填するステップと、
・前記チャネル内に前記空気出口及び前記空気入口を提供する別個の部分を有するチューブを配置するステップであって、前記空気出口が、前記空気入口よりも前記ボウルから遠くにあり、前記チューブが、前記チャネルの上部と同じ高さの平坦な上側を有する、ステップと、
・蓋材で前記空洞を封止するステップと、同時に、またはいずれかの順序で、
・取り外されたときに、前記空気入口及び前記空気出口を露出させる着脱可能部分を形成するステップと、
・個々のディスペンサ、または複数対のディスペンサ、または複数のディスペンサを有するストリップを形成するために、前記基部材及び蓋材を切断するステップと、
を含む、プロセス。 - 前記着脱可能部分が、前記基部材及び/または前記蓋材に穿孔または刻み目などの脆弱線を作成することによって形成される、請求項10に記載のプロセス。
- 前記着脱可能部分が、前記基部材及び/または前記蓋材の一方または両方の縁部にノッチを作成することによって形成される、請求項10または11に記載のプロセス。
- 前記蓋材を前記チューブの前記平坦な上側に接合するステップをさらに含む、請求項10から12のいずれか一項に記載のプロセス。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20192645.8 | 2020-08-25 | ||
EP20192645 | 2020-08-25 | ||
EP21172658.3 | 2021-05-07 | ||
EP21172658 | 2021-05-07 | ||
PCT/EP2021/073418 WO2022043336A1 (en) | 2020-08-25 | 2021-08-24 | Unit dose dry powder inhaler |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023539600A JP2023539600A (ja) | 2023-09-15 |
JP7477719B2 true JP7477719B2 (ja) | 2024-05-01 |
Family
ID=77640690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023513476A Active JP7477719B2 (ja) | 2020-08-25 | 2021-08-24 | 単位用量乾燥粉末吸入器 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230293831A1 (ja) |
EP (1) | EP4204048A1 (ja) |
JP (1) | JP7477719B2 (ja) |
CN (1) | CN115956053A (ja) |
BR (1) | BR112023001020A2 (ja) |
CA (1) | CA3185588A1 (ja) |
MX (1) | MX2023002040A (ja) |
WO (1) | WO2022043336A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130291865A1 (en) | 2012-05-03 | 2013-11-07 | Manta Devices, Llc | Delivery device and related methods |
JP2020515366A (ja) | 2017-03-28 | 2020-05-28 | コンセントリクス ファーマシューティカルズ,インコーポレイテッド | 乾燥粉末薬物を送達するための装置および方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8914223D0 (en) | 1989-06-21 | 1989-08-09 | Fisons Plc | Medicament container |
WO2003103563A2 (en) | 2002-06-07 | 2003-12-18 | Sun Pharmaceutical Industries Limited | Powder inhaler |
GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
GB2425115A (en) | 2005-04-15 | 2006-10-18 | Vectura Group Plc | Blister pack |
GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
GB0901520D0 (en) | 2009-01-30 | 2009-03-11 | Vectura Delivery Devices Ltd | Inhaler |
BR112014004921B1 (pt) * | 2011-09-07 | 2020-12-08 | Concentrx Pharmaceuticals, Inc. | dispositivo de inalação de pó seco |
SE1300485A1 (sv) | 2013-04-23 | 2014-10-24 | Simplified Solutions Sweden Ab | Engångs-inhalator för ämnen i pulverform |
DE102014017409B4 (de) | 2014-11-26 | 2016-06-09 | Klaus Dieter Beller | Einzeldosis-Pulverinhalator und Verfahren zu dessen Herstellung |
-
2021
- 2021-08-24 BR BR112023001020A patent/BR112023001020A2/pt unknown
- 2021-08-24 MX MX2023002040A patent/MX2023002040A/es unknown
- 2021-08-24 CA CA3185588A patent/CA3185588A1/en active Pending
- 2021-08-24 JP JP2023513476A patent/JP7477719B2/ja active Active
- 2021-08-24 EP EP21765931.7A patent/EP4204048A1/en active Pending
- 2021-08-24 CN CN202180051788.7A patent/CN115956053A/zh active Pending
- 2021-08-24 WO PCT/EP2021/073418 patent/WO2022043336A1/en unknown
- 2021-08-24 US US18/020,530 patent/US20230293831A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130291865A1 (en) | 2012-05-03 | 2013-11-07 | Manta Devices, Llc | Delivery device and related methods |
JP2020515366A (ja) | 2017-03-28 | 2020-05-28 | コンセントリクス ファーマシューティカルズ,インコーポレイテッド | 乾燥粉末薬物を送達するための装置および方法 |
Also Published As
Publication number | Publication date |
---|---|
CA3185588A1 (en) | 2022-03-03 |
EP4204048A1 (en) | 2023-07-05 |
MX2023002040A (es) | 2023-03-15 |
US20230293831A1 (en) | 2023-09-21 |
BR112023001020A2 (pt) | 2023-04-11 |
WO2022043336A1 (en) | 2022-03-03 |
JP2023539600A (ja) | 2023-09-15 |
CN115956053A (zh) | 2023-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8286631B2 (en) | Dry powder inhalation device for the simultaneous administration of more than one medicament | |
JP2005509460A (ja) | ユニット用量粉末容器 | |
FI88112B (fi) | Anordning foer administrering av laekemedel till patienter | |
CN101489613A (zh) | 用于对干粉状药物进行给药的吸入系统和递送装置 | |
PL185314B1 (pl) | Inhalator | |
BRPI0919044B1 (pt) | conjunto de recipientes de dose de pó seco, inalador de pó seco, e, método para fabricar um conjunto de recipientes de dose | |
JP2008501472A (ja) | ドライパウダー吸入器 | |
JP5394440B2 (ja) | 吸入器 | |
JP7477719B2 (ja) | 単位用量乾燥粉末吸入器 | |
WO2009102273A1 (en) | Inhaler comprising a plurality of consecutive sealed cavities containing medicaments | |
CA3214327A1 (en) | Unit dose dry powder inhaler | |
US20230118029A1 (en) | Process for manufacturing a blister strip for a dry powder inhaler | |
US11524128B2 (en) | Blister pack and inhaler comprising the same | |
EP4061455B1 (en) | Inhaler for use with a compliance monitor | |
WO2021255036A1 (en) | Blister pack and inhaler comprising the same | |
CN115916305A (zh) | 多载体药物分配器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230421 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240308 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240325 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240418 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7477719 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |